NCT00441974View on ClinicalTrials.gov

Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

1,470

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Chronic Hepatitis B
Interventions
DRUG

adefovir dipivoxil

adefovir dipivoxil once daily one tablet 10mg orally

Trial Locations (25)

100011

GSK Investigational Site, Beijing

100044

GSK Investigational Site, Beijing

100050

GSK Investigational Site, Beijing

100069

GSK Investigational Site, Beijing

130021

GSK Investigational Site, Changchun

200001

GSK Investigational Site, Shanghai

200003

GSK Investigational Site, Shanghai

200025

GSK Investigational Site, Shanghai

200040

GSK Investigational Site, Shanghai

200433

GSK Investigational Site, Shanghai

210002

GSK Investigational Site, Nanjing

210003

GSK Investigational Site, Nanjing

210029

GSK Investigational Site, Nanjing

250021

GSK Investigational Site, Jinan

300192

GSK Investigational Site, Tianjin

310003

GSK Investigational Site, Hangzhou

350025

GSK Investigational Site, Fuzhou

400038

GSK Investigational Site, Chongqing

GSK Investigational Site, Chongquin

410008

GSK Investigational Site, Changsha

410011

GSK Investigational Site, Changsha

430030

GSK Investigational Site, Wuhan

510515

GSK Investigational Site, Guangzhou

510630

GSK Investigational Site, Guangzhou

610041

GSK Investigational Site, Chengdu

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00441974 - Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients | Biotech Hunter | Biotech Hunter